TW201329094A - 有機矽化合物及含該化合物之矽烷偶合劑 - Google Patents
有機矽化合物及含該化合物之矽烷偶合劑 Download PDFInfo
- Publication number
- TW201329094A TW201329094A TW101133127A TW101133127A TW201329094A TW 201329094 A TW201329094 A TW 201329094A TW 101133127 A TW101133127 A TW 101133127A TW 101133127 A TW101133127 A TW 101133127A TW 201329094 A TW201329094 A TW 201329094A
- Authority
- TW
- Taiwan
- Prior art keywords
- coupling agent
- cells
- decane coupling
- cell
- represented
- Prior art date
Links
- 150000003377 silicon compounds Chemical class 0.000 title abstract 3
- 239000006087 Silane Coupling Agent Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 79
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 76
- 239000000758 substrate Substances 0.000 claims description 60
- 239000007822 coupling agent Substances 0.000 claims description 38
- -1 hydrazine compound Chemical class 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
- 210000001082 somatic cell Anatomy 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002798 polar solvent Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000001463 antimony compounds Chemical class 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000011521 glass Substances 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 210000001772 blood platelet Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229940125782 compound 2 Drugs 0.000 description 7
- 102000034287 fluorescent proteins Human genes 0.000 description 7
- 108091006047 fluorescent proteins Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 239000012756 surface treatment agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 108010006205 fluorescein isothiocyanate bovine serum albumin Proteins 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000004381 surface treatment Methods 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 150000003304 ruthenium compounds Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N alpha-methacrylic acid Natural products CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012237 artificial material Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001785 cerium compounds Chemical class 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- LHGMHYDJNXEEFG-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]iminocyclohexa-2,5-dien-1-one Chemical compound C1=CC(N(C)C)=CC=C1N=C1C=CC(=O)C=C1 LHGMHYDJNXEEFG-UHFFFAOYSA-N 0.000 description 1
- 206010048781 Accessory kidney Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LLGHYVXTTIEZPZ-UHFFFAOYSA-N C(C)OC(CCCCCCCCC)(C)C Chemical compound C(C)OC(CCCCCCCCC)(C)C LLGHYVXTTIEZPZ-UHFFFAOYSA-N 0.000 description 1
- OABPMUYZZLHPJR-UHFFFAOYSA-N CC(=COCCP)C Chemical compound CC(=COCCP)C OABPMUYZZLHPJR-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229910018879 Pt—Pd Inorganic materials 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000487 effect on differentiation Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002098 polyfluorene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- NCNTUSIQHIOVLD-UHFFFAOYSA-N trimethyl-[3-(prop-1-enylamino)propyl]azanium Chemical compound C[N+](C)(C)CCCNC=CC NCNTUSIQHIOVLD-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/16—Antifouling paints; Underwater paints
- C09D5/1606—Antifouling paints; Underwater paints characterised by the anti-fouling agent
- C09D5/1612—Non-macromolecular compounds
- C09D5/1625—Non-macromolecular compounds organic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/424—Anti-adhesion agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials Engineering (AREA)
- Wood Science & Technology (AREA)
- Materials For Medical Uses (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
[課題]本發明之課題為提供一種可使用於矽烷偶合劑之新穎有機矽化合物。[解決手段]解決課題之技術手段為提供一種下述式(1)：□(式中，A-表示為下述式(2)或式(3)：□，E表示為下述式(4)或式(5)：□，R1及R2各自獨立表示為碳原子數1至5之烷基，R3表示為氫原子或甲基，R4及R5各自獨立表示為碳原子數1至5之烷基，m、n及p各自獨立表示為1至5之整數，q表示為1至3之整數)所代表之有機矽化合物。
Description
本發明係關於藉由對矽、玻璃等之無機物質、或聚乙烯等之樹脂進行表面處理，可抑制蛋白質等之生物體物質、血小板等之細胞的附著，一分子內具有安定之正負雙電荷之甜菜鹼型或磺基甜菜鹼型有機矽化合物。
生物體系統與人工材料等外在物相接觸時，因為人體會將該人工材料認作為異物，伴隨時間經過而引起血栓形成、免疫反應、炎症反應等各種之異物反應。因此，使用人工臟器等之醫療用器具時，不得不併用如肝素等之抗凝血劑、免疫抑制劑之類的藥劑。
然而，使用上述抗凝血劑等的情況時，擔心會產生肝臟損害、過敏性反應等之各式各樣的副作用。
因此，為了解決這些問題，有提案使用在高分子鏈之側鏈上具有與生物體膜相同之兩性型磷脂之磷醯膽鹼之聚(2-甲基丙烯醯氧乙基磷醯膽鹼)(以下，在本說明書稱為MPC聚合物的醫療用材料(例如，參照專利文獻1及專利文獻2)。
又，有提案使用N-甲基丙烯醯氧乙基-N,N-二甲基銨-α-N-甲基羧基甜菜鹼之高分子量體(以下，在本說明書稱為CMB聚合物)之醫療用材料(例如，參照專利文獻3、專利文獻4及專利文獻5)。
藉由將MPC聚合物或CMB聚合物被覆於材料表面，即使不使用抗凝血劑的情況下亦可抑制血液凝固。
[專利文獻1]日本特開昭54-63025號公報
[專利文獻2]日本特開2000-279512號公報
[專利文獻3]日本特開2007-130194號公報
[專利文獻4]日本特開2008-274151號公報
[專利文獻5]日本特開2010-57745號公報
然而，從MPC聚合物及CMB聚合物之合成，進一步到製造含有該聚合物溶液之步驟有耗費時間的問題。本發明之課題，在於由製造溶液，可直接被覆於基材之表面上，然而可提供顯示與以往之MPC聚合物及CMB聚合物同等效果之非聚合物。
本發明者們，為解決上述課題，不附著蛋白質等之生物體物質、血小板等之細胞，發現於一分子內具有安定正負雙電荷之甜菜鹼型或磺基甜菜鹼型有機矽化合物。
亦即，本發明態樣之一種係如下述式(1)：
(式中，A-表示為下述式(2)或式(3)：
，E表示為下述式(4)或式(5)：
，前述式(4)及式(5)中之羰基表示為與鍵結R3之碳原子鍵結，R1及R2各自獨立表示為碳原子數1至5之烷基，R3表示為氫原子或甲基，R4及R5各自獨立表示為碳原子數1至5之烷基，m、n及p各自獨立表示為1至5之整數，q表示為1至3之整數)所代表之有機矽化合物。
本發明之其他態樣，係含有前述有機矽化合物、極性有機溶劑及水之矽烷偶合劑(表面處理劑)。
進而本發明之其他態樣，係由前述矽烷偶合劑所構成之生物體物質或細胞之黏著抑制劑。
又，本發明之其他態樣，係含有將前述矽烷偶合劑塗
佈於基材或將基材浸漬於該矽烷偶合劑中之步驟的矽烷偶合劑固定化方法。
藉由使用含有本發明之有機矽化合物之矽烷偶合劑(表面處理劑)，使矽、玻璃等之無機物質或聚乙烯等之樹脂(以下，在本說明書稱為基材)的表面處理變為可能，該表面被覆以一分子內具有安定之正負雙電荷之甜菜鹼或磺基甜菜鹼。因此，未使用如MPC聚合物、CMB聚合物之類的聚合物，蛋白質等之生物體物質、血小板等之細胞可不附著於上述無機物質或樹脂表面上。
前述式(1)所代表之有機矽化合物，例如可藉由使其與甜菜鹼及氫硫基矽烷反應而合成。
作為前述式(1)所代表之有機矽化合物之原料的甜菜鹼，例如以N-甲基丙烯醯氧乙基-N,N-二甲基銨-α-N-甲基羧基甜菜鹼、N-甲基丙烯醯氧乙基-N,N-二甲基銨-α-N-丙基亞碸基甜菜鹼、N-甲基丙烯醯基胺基丙基-N,N-二甲基銨-α-N-丙基亞碸基甜菜鹼為佳。
又，作為前述式(1)所代表之有機矽化合物之另一個原料的氫硫基矽烷，例如以3-氫硫基丙基三甲氧基矽烷、3-氫硫基丙基三乙氧基矽烷、3-氫硫基丙基甲基二甲氧基矽烷、(氫硫基甲基)二甲氧基矽烷、(氫硫基甲基
)二甲基乙氧基矽烷及氫硫基甲基三甲氧基矽烷為佳。
將上述有機矽化合物用於作為基材之無機物質的表面處理時，該無機物質並未特別限制。例如可列舉矽、銅、鐵、鋁、鎳或該等之合金、玻璃、二氧化矽、氧化鋁、氫氧化鋁、氧化鎂。
將上述有機矽化合物用於作為基材之樹脂的表面處理時，該樹脂並未特別限制。例如可列舉聚乙烯、聚丙烯、聚苯乙烯、聚氯乙烯、尼龍、聚胺基甲酸乙酯、聚脲、聚乳酸、聚乙醇酸、聚乙烯醇、聚乙酸乙烯酯、聚(甲基)丙烯酸、聚(甲基)丙烯酸衍生物、聚丙烯腈、聚(甲基)丙烯醯胺、聚(甲基)丙烯醯胺衍生物、聚碸、聚碳酸酯、纖維素、纖維素衍生物。
上述有機矽化合物，係可用於醫藥品、醫藥部外品、醫療用器具等之表面處理。作為前述醫療用器具之例子可列舉藥物傳送系統材料、成型輔助材料、包裝材、人工血管、血液透析膜、導管、保護線、隱形眼鏡、血液過濾器、儲血包、內視鏡、人工臟器、生物體晶片、細胞培養薄片、糖鏈合成機器，該醫療用器具並未特別限制。
在本說明書所謂生物體物質，係指構成生物體之基本材料，例如可列舉蛋白質、核酸、各種糖類、胺基酸、核苷、脂質、維他命。此等之生物體物質之內，藉由使用含有本發明之有機矽化合物之矽烷偶合劑(表面處理劑)作為抑制附著之生物體物質，可列舉蛋白質、核酸、各種糖類、胺基酸、核苷、脂質、維他命，較佳為蛋白質、核酸
、各種糖類，更佳為蛋白質。
在本說明書所謂細胞，係指構成生物體最基本的單位，作為該要素係於細胞膜之內部具有細胞質與各種細胞小胞器者。此時，內包DNA之核，可含在細胞內部亦可不含。例如在本發明之來自動物的細胞中，包含精子、卵子等之生殖細胞、構成生物體之體細胞、幹細胞、前驅細胞、分離自生物體之癌細胞、分離自生物體之獲得永生化功能(Immortalization)並穩定維持於體外之細胞(細胞株)、分離自生物體之經人工遺傳修飾所成之細胞、分離自生物體之經人工交換核之細胞等。作為構成生物體之體細胞示例，並非限於以下者，其係包含成纖維細胞、骨髓細胞、B淋巴球、T淋巴球、嗜中性血球(Neutrophil)、紅血球、血小板、巨噬細胞、單核球、骨細胞、骨髓細胞、外被細胞、樹枝狀細胞、角質細胞、脂肪細胞、間質細胞(Mesenchymal cell)、上皮細胞、表皮細胞、內皮細胞、血管內皮細胞、肝實質細胞、軟骨細胞、卵丘細胞、神經系細胞、膠質細胞、神經元、神經間膠細胞(Oligodendrocyte)、小神經膠質、星狀膠細胞、心臟細胞、食道細胞、肌肉細胞(例如，平滑肌細胞、骨骼肌細胞)、胰臟β細胞、黑色素細胞、造血前驅細胞、及單核細胞。上述體細胞，例如包含皮膚、腎臟、脾臟、副腎、肝臟、肺、卵巢、胰臟、子宮、胃、結腸、小腸、大腸、膀胱、前列腺、睪丸、胸腺、肌肉、結締組織、骨、軟骨、血管組織、血液、心臟、眼、腦、神經組織等採取自任意
組織的細胞。所謂上述幹細胞，係指兼具複製本身之能力與分化至其他複數系統細胞之能力的細胞，作為該示例，並不限於以下者，包含胚胎的幹細胞(ES細胞)、胚胎的腫瘍細胞、胚胎的生殖幹細胞、人工多功能性幹細胞(iPS細胞)、神經幹細胞、造血幹細胞、間葉活動(Mesenchymal)幹細胞、肝幹細胞、胰臟幹細胞、肌肉幹細胞、生殖幹細胞、腸幹細胞、癌幹細胞、毛囊幹細胞等。所謂上述前驅細胞，係指從前述幹細胞分化為特定的體細胞或生殖細胞的中途段階之細胞。所謂上述癌細胞，係指從體細胞獲得所衍生之無限增殖能之細胞。所謂上述細胞株，係指經於生物體外之人為操作獲得無限增殖能之細胞，作為該示例，並非限定於以下者，包含HCT 116、Huh7、HEK 293(人類胎兒腎細胞)、HeLa(人類子宮頸癌細胞株)、Hep G2(人類肝癌細胞株)、UT7/TPO(人類白血病細胞株)、CHO(中國倉鼠卵巢細胞株)、MDCK、MDBK、BHK、C-33A、HT-29、AE-1、3D9、Ns0/1、Jurkat、NIH3T3、PC12、S2、Sf9、Sf21、High Five、Vero。
這些細胞內，作為經由使用含有本發明之有機矽化合物之矽烷偶合劑(表面處理劑)抑制附著之細胞，可列舉精子或卵子等之生殖細胞、構成生物體之體細胞、幹細胞、前驅細胞、分離自生物體之癌細胞，分離自生物體之獲得永生化功能並穩定維持在體外之細胞(細胞株)、分離自生物體之人工遺傳修飾所成之細胞、分離自生物體之經
人工交換核之細胞，較佳可列舉構成生物體之體細胞、幹細胞、前驅細胞、分離自生物體之癌細胞、分離自生物體之獲得永生化功能並穩定維持在體外之細胞(細胞株)，更佳可列舉構成生物體之體細胞、分離自生物體之癌細胞、分離自生物體之獲得永生化功能並穩定維持在體外之細胞(細胞株)，進一步特佳可列舉構成生物體之體細胞，最佳可列舉血小板。
含有本發明之有機矽化合物之矽烷偶合劑(表面處理劑)，因為抑制生物體物質、細胞之附著效率良好，故可作為生物體物質、細胞之研究用試藥使用。例如，解析細胞或組織之分化、解明調節增殖之因素之際，將細胞與目的之因素使其共存而得到經培養時之細胞與得自該細胞之生物體物質的數量或種類、細胞表面分化標識物、表現基因之變化。在這時藉由使用本發明之矽烷偶合劑因為能抑制生物體物質、細胞之附著，故可有效率地回收目的之生物體物質、細胞。進行解明作為目的之因素時之培養條件、培養裝置、培養基之種類、矽烷偶合劑之種類、該含量、添加物之種類、添加物之含量、培養期間、培養溫度等，經由該領域具有通常技術者做適當選擇。由培養增殖或經表現細胞，在本發明相關之技術領域上可使用標準顯微鏡進行觀察。此時，亦可對經培養之細胞使用特異的抗體進行染色。藉由目的因素之已變化的表現基因，從經培養之細胞萃取DNA(去氧核糖核酸)或RNA(核糖核酸)，可藉由南方點漬法(Southern blotting)、北方點漬法
(Northern blotting)、RT-PCR法等檢出。又，細胞表面分化標識物，係使用特異的抗體由ELISA或流式細胞儀(Flow cytometry)檢出，依據目的之因素可觀察對分化或增殖之效果。
含有本發明之有機矽化合物之矽烷偶合劑(表面處理劑)，例如，於該有機矽化合物加入水及甲醇、乙醇、丙二醇單甲基醚等之極性有機溶劑稀釋而調製成0.001質量%至20質量%。為了調整前述矽烷偶合劑之pH，亦可進一步添加有機酸。作為前述有機酸，例如可列舉乙酸、蟻酸、乳酸。
將前述基材用本發明之矽烷偶合劑進行表面處理之方法並沒有特別限定，例如可藉由浸漬、塗佈(旋塗、噴塗等)或蒸鍍處理。
具體而言，經過將本發明之矽烷偶合劑塗佈於基材上並烘烤之步驟，之後用極性溶劑洗淨前述基材之步驟、及乾燥前述基材之步驟將矽烷偶合劑固定化。或是經過將基材浸漬於前述矽烷偶合劑中之步驟、之後用極性溶劑洗淨前述基材之步驟、及乾燥前述基材之步驟將矽烷偶合劑固定化。作為使用於洗淨步驟之極性溶劑，例如可使用前述矽烷偶合劑所含有之水或極性有機溶劑。
以下，對關係本發明之具體例進行說明，並非藉由此加以限定本發明。還有，在CO2恆溫箱CO2之濃度(%
)，以環境中CO2之體積%表示。又，PBS係意味磷酸緩衝生理食鹽水(Sigma-Aldrich公司製)，FBS係意味牛胎兒血清(Biological Industries公司製)。
將具備磁力攪拌器之500ml四口燒瓶中，加入化合物120.03g、(3-氫硫基丙基)三乙氧基矽烷22.15g、三乙胺0.48g及乙醇80g，室溫下攪拌24小時。濃縮乾燥反應液，得到40.56g化合物2(產量：96%)。
[化5]
1H-NMR(400MHz)in CDCl3：0.69-0.74ppm(m,2H),1.23ppm(t,J=7.0 Hz,9H),
1.22-1.28ppm(m,3H),1.62-1.73ppm(m,2H),2.51-2.56ppm(m,2H),2.57-2.68ppm(m,1H),2.69-2.80ppm(m,2H),3.37ppm(s,6H),3.81ppm(q,J=7.0 Hz,6H),3.96ppm(s,2H),4.06-4.21ppm(m,2H),4.47-4.63ppm(m,2H)
將具備磁力攪拌器之300ml四口燒瓶中，加入化合物315.00g、(3-氫硫基丙基)三乙氧基矽烷12.81g、三乙胺1.09g、乙醇60g及甲醇20g，室溫下攪拌2小時。濃
縮反應液後，加入己烷60g，過濾乾燥析出之結晶，得到13.81g化合物4(產量：50%)。
[化7]
1H-NMR(400MHz)in CDCl3：0.68-0.76ppm(m,2H),1.23ppm(t,J=7.0 Hz,9H),
1.22-1.28ppm(m,3H),1.62-1.72ppm(m,2H),2.21-2.34ppm(m,2H),2.53ppm(dd,J=7.0 Hz,8.2 Hz,2H),2.55-2.65ppm(m,1H),2.68-2.80ppm(m,2H),2.85-2.94ppm(m,2H),3.29ppm(s,6H),3.74-3.87ppm(m,4H),3.81ppm(q,J=7.0 Hz,6H),4.56-4.62ppm(m,2H)
於PGME(丙二醇單甲基醚)/水=9/1體積%濃度之溶劑加入乙酸，調製成pH4.0。之後，以合成例1及合成例2所得到之有機矽化合物各自溶解於前述溶劑調製成1質量%濃度之矽烷偶合劑。
將玻璃基板(TEMPAX Float〔登錄商標〕，50×50mm、厚度lmm)浸漬於含有於合成例1所得到之化合物2之10ml矽烷偶合劑中，於40℃靜置24小時。將該玻璃基板從前述矽烷偶合劑取出之後，以PGME洗淨，並風乾。
將與在實施例1所使用之玻璃基板同種之玻璃基板浸漬於含有於合成例2所得到之化合物2之10ml矽烷偶合劑中，於40℃靜置24小時。將該玻璃基板從前述矽烷偶合劑取出之後，以PGME洗淨，並風乾。
將含有在合成例1所得到之化合物2之0.5ml矽烷偶合劑，於與實施例1所使用之玻璃基板同種之玻璃基板上使用旋轉塗佈機進行塗佈，在熱板上以100℃烘烤15分鐘。之後，以PGME洗淨，並風乾。
將含有在合成例2所得到之化合物4之0.5ml矽烷偶合劑，於與實施例1所使用之玻璃基板同種之玻璃基板上使用旋轉塗佈機進行塗佈，在熱板上以100℃烘烤15分鐘。之後，以PGME洗淨，並風乾。
將與實施例1所使用之玻璃基板同種之玻璃基板以PGME洗淨，並風乾。
對以經實施例1至實施例4及比較例1處理之各玻璃基板的表面使用水及二碘甲烷進行接觸角測定。使用接觸角計(協和界面科學(股)製)用液滴法測定，以θ/2法算出接觸角。其結果表示於下述表1。
將經螢光標識之牛血清白蛋白(FITC-BSA，Sigma-Aldrich公司製)溶解於磷酸生理食鹽水(PBS，pH7.4)，調製成100 μg/ml之FITC-BSA溶液。將此FITC-BSA溶液0.5ml添加於經實施例1至實施例4及比較例1處理之各玻璃基板的表面上，於37℃靜置30分鐘。之後，從前述各玻璃基板之表面去除FITC-BSA溶液，使用PBS作為溶劑進行洗淨，並風乾。
使用螢光顯微鏡(奧林巴斯(股)製)於波長490nm激發10秒，於波長520nm進行螢光測定，在螢光強度確認FITC-BSA之吸附。該結果表示於下述表1。
接觸角測定之結果，經實施例1至實施例4處理之各玻璃基板對於經比較例1處理之玻璃基板(無螢光蛋白質處理)，發現對水及二碘甲烷之接觸角的減少。由此認為，將含有化合物2之矽烷偶合劑及含有化合物4之矽烷偶合劑，塗佈於玻璃基板上。
螢光蛋白質之吸附實驗的結果，對於經比較例1處理之玻璃基板(有螢光蛋白質處理)之螢光強度，經實施例1及實施例2處理之各玻璃基板的螢光強度下降，與經比較例1處理之玻璃基板(無螢光蛋白質處理)變為同等。此結果，使化合物2及化合物4之正負兩離子性部位配置於玻璃基板表層，認為是為阻止螢光蛋白質之吸附。經實施例3及實施例4處理之各玻璃基板的螢光強度也是，又經比較例1處理之玻璃基板(有螢光蛋白質處理)的螢光強度更加降低，抑制螢光蛋白質之吸附。
將於合成例1及合成例2所得到之有機矽化合物各自溶解於99.5體積%乙醇(含有0.5體積%之水)調製成10mM溶液之矽烷偶合劑。
將在O2蝕刻之經表面洗淨之玻璃基板(TEMPAX Float〔登錄商標〕，12mm、厚度1mm)浸漬於含有以合成例1所得到之化合物2之10mM乙醇溶液100ml中，於室溫靜置48小時。將該玻璃基板從前述之溶液取出後，以乙醇洗淨，並風乾。
將與在實施例5所使用之玻璃基板同種之玻璃基板浸
漬於含有以合成例2所得到之化合物4之10mM乙醇溶液100ml中，於室溫靜置48小時。將該玻璃基板從前述之溶液取出後，以乙醇洗淨，並風乾。
將與在實施例5所使用之玻璃基板同種之玻璃基板保管在塑料外殼內1週。
對3.8質量%檸檬酸鈉溶液0.5ml，混和從健康志願者所採之血液4.5ml之後，於離心分離〔冷卻離心機5900((股)久保田製作所製)，1000rpm/10分鐘、室溫〕回收上層之富血小板血漿(PRP)。接著，對於下層進行離心分離(上述離心機，3500rpm/10分鐘、室溫)，回收上層之貧血小板血漿(PPP)。在多項目自動紅血球分析裝置(XT-2000i，Sysmex(股)製)測量PRP之血小板數之後，使用PPP將PRP之血小板濃度調製成30×104cells/μL。
配置經實施例5、實施例6及比較例2處理之各玻璃基板於24穴平底小板塊(康寧公司製)上，添加上述血小板濃度已調製成PRP溶液300 μL。將二氧化碳濃度保持在5%狀態，於37℃靜置在CO2恆溫箱內90分鐘。去
除盤內之PRP後，以3ml磷酸緩衝生理食鹽水(PBS)洗淨5次。之後，添加2.5體積%戊二醛之PBS溶液2ml，在4℃靜置一晝夜後，去除戊二醛之PBS溶液，以3ml超純水(Milli-Q水)洗淨5次。進一步，以1ml 70%乙醇水(v/v)洗淨3次，並風乾。此實驗進行2次(Run-1、Run-2)。
進行上述血小板附著實驗之經實施例5、實施例6及比較例2處理之各玻璃基板上，用離子濺射(E-1030，日立高科技(股)製)將Pt-Pd進行1分鐘蒸鍍。之後，在電子顯微鏡(S-4800，日立高科技(股)製)以1,000倍觀察血小板之附著。
在電子顯微鏡測量玻璃基板內5處之血小板附著數。藉由平均各處之測量值，作為Run-1或Run-2之血小板附著數。進一步藉由平均Run-1與Run-2之血小板附著數，比較經實施例5、實施例6及比較例2處理之各玻璃基板的血小板之附著性。該結果表示於下述表2。
血小板附著實驗之結果，在經比較例2處理之玻璃基板其附著物多，血小板附著數之測量困難。另一方面，在經實施例5及實施例6處理之各玻璃基板，可測量血小板附著數，比經比較例2處理之玻璃基板明顯看出附著物為少。
細胞，使用人類胚胎腎臟細胞株Hek293(DS Pharma Biomedical公司製)、人類肝癌細胞株Hep G2(DS Pharma Biomedical公司製)、人類子宮頸癌細胞株HeLa(DS Pharma Biomedical公司製)、人類胚胎肺細胞株MRC5(DS Pharma Biomedical公司製)、及中國倉鼠卵巢細胞株CHO(DS Pharma Biomedical公司製)。用於該等細胞之培養之培養基，使用HeLa、Hek293及MRC5：含有10%(v/v)FBS之EMEM培養基(和光純藥工業(股)製)、Hep G2：含有10%(v/v)FBS之DMEM培養基(和光純藥工業(股)製)、CHO：含有10%(v/v)FBS之DMEM/F-12培養基(Sigma-Aldrich公司製)。細胞，在37℃CO2恆溫箱內將二氧化碳濃度保持在5%狀態，使用直徑10cm之淺盤(培養基10ml)靜置2天以上培養。接下來，將本細胞以PBS5ml洗淨之後，添加胰蛋白-EDTA溶液(Invitrogen公司製)1ml然後剝離細胞，懸濁在上述之培養基10ml。將本懸濁液離心分離(用於上述血小板溶液之調製之離心機，1500rpm/3分鐘、室溫
)後，除去上清，添加上述之培養基調製細胞懸濁液。
配置經實施例5、實施例6及比較例2處理之各玻璃基板於24穴平底小板塊(康寧公司製)上，將已調製成之上述細胞懸濁液成為2.5×105cells/well各加入1ml。之後，保持在5%二氧化碳濃度之狀態下，靜置在37℃CO2恆溫箱內24小時。
24小時後，將進行上述細胞附著實驗之經實施例5、實施例6及比較例2處理之各玻璃基板移轉到別的24穴平底小板塊，以PBS1ml洗淨。去除PBS之後，添加胰蛋白-EDTA溶液(Invitrogen公司製)500 μL。5分~10分鐘後，將含有10%(v/v)FBS之DMEM培養基(和光純藥工業(股)製)添加500 μL，將剝離的細胞移送到1.5ml微量試管(Eppendorf公司製)。經離心分離(TOMY精工(股)製，型號：MX-307，1500rpm/3分鐘、室溫)後、除去上清，添加含有10%(v/v)FBS之DMEM培養基(和光純藥工業(股)製)100 μL調製成細胞懸濁液。等量添加台酚藍染色液於本懸濁液之後，在血球測量板(艾爾瑪銷售有限公司製)測量生細胞數(細胞附著數)。
培養24小時後，對經實施例5、實施例6及比較例2
處理之各玻璃基板比較細胞之附著數。該結果表示於下述表3。表3中，“-”係表示細胞附著數測量困難。
細胞附著實驗之結果，培養24小時後，對於經比較例2處理之玻璃基板，在經實施例5及實施例6處理之各玻璃基板，任一種情形之細胞的細胞附著數皆下降。
Claims (8)
- 一種有機矽化合物，其係下述式(1)所代表之有機矽化合物：
- 一種矽烷偶合劑，其係含有如申請專利範圍第1項所記載之有機矽化合物、極性有機溶劑及水者。
- 如申請專利範圍第2項之矽烷偶合劑，其中進一步含有有機酸。
- 一種黏著抑制劑，其係由申請專利範圍第2項或第3項所記載之矽烷偶合劑所構成之生物體物質或細胞者。
- 如申請專利範圍第4項之黏著抑制劑，其中前述細胞係從構成生物體之體細胞、分離自生物體之癌細胞、或分離自生物體之獲得永生化功能並穩定維持於體外之細胞。
- 如申請專利範圍第4項之黏著抑制劑，其中前述細胞為血小板。
- 一種矽烷偶合劑固定化方法，其係含有以下之步驟：將如申請專利範圍第2項或第3項所記載之矽烷偶合劑塗佈於基材上烘烤之步驟、之後以極性溶劑洗淨前述基材之步驟、及乾燥前述基材之步驟。
- 一種矽烷偶合劑固定化方法，其係含有有以下之步驟：將基材浸漬於如申請專利範圍第2項或第3項所記載之矽烷偶合劑中之步驟、之後以極性溶劑洗淨前述基材之步驟、及乾燥前述基材之步驟。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011203681 | 2011-09-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201329094A true TW201329094A (zh) | 2013-07-16 |
| TWI565710B TWI565710B (zh) | 2017-01-11 |
Family
ID=47883135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW101133127A TWI565710B (zh) | 2011-09-16 | 2012-09-11 | 有機矽化合物及含該化合物之矽烷偶合劑 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9340561B2 (zh) |
| JP (1) | JP6150071B2 (zh) |
| TW (1) | TWI565710B (zh) |
| WO (1) | WO2013038901A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105744966A (zh) * | 2013-11-28 | 2016-07-06 | 东丽株式会社 | 抗血栓性材料 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2816899B1 (en) | 2012-02-24 | 2019-08-28 | GOJO Industries, Inc. | Antimicrobial and foamable alcoholic compositions |
| JPWO2013176084A1 (ja) * | 2012-05-22 | 2016-01-14 | 日産化学工業株式会社 | シリルアルキルホスホラミダード化合物を含むシランカップリング剤 |
| CN104854115B (zh) * | 2013-03-25 | 2017-11-14 | 住友理工株式会社 | 反应性离子液体和使用其的离子固定化金属氧化物颗粒、离子固定化弹性体以及转换器 |
| WO2015008834A1 (ja) * | 2013-07-18 | 2015-01-22 | 日産化学工業株式会社 | 活性エステル基を含有するシラン化合物とそれを用いた材料 |
| US20180362552A1 (en) * | 2015-04-15 | 2018-12-20 | Kri, Inc. | Betaine-based silicon compound, method for producing same, hydrophilic coating liquid composition, and coating film |
| JP6531124B2 (ja) * | 2016-10-07 | 2019-06-12 | 株式会社Kri | スルホベタイン系ケイ素系化合物の製造方法 |
| EP3747985A4 (en) * | 2018-02-01 | 2021-10-27 | Agc Inc. | CELL CULTURE CONTAINER |
| JP2020097542A (ja) * | 2018-12-18 | 2020-06-25 | Ａｇｃセイミケミカル株式会社 | アルコキシシリル基含有フッ素化合物の製造方法、表面処理組成物の製造方法、および表面処理された部材の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6021599B2 (ja) | 1977-10-28 | 1985-05-28 | 株式会社クラレ | ２−メタクリルオキシエチルホスホリルコリン |
| IL111497A (en) | 1993-12-08 | 2001-01-28 | Rohco Inc Mcgean | Seelan preparations are useful as adhesives |
| JP3555801B2 (ja) * | 1996-04-30 | 2004-08-18 | 株式会社日鉱マテリアルズ | 新規有機ケイ素化合物およびその製造方法並びにそれを用いる表面処理剤および樹脂添加剤 |
| JP4712924B2 (ja) | 1999-03-30 | 2011-06-29 | 日油株式会社 | 医療用材料および製造方法 |
| JP4961133B2 (ja) | 2005-11-10 | 2012-06-27 | 大阪有機化学工業株式会社 | 医療用材料 |
| JP5107605B2 (ja) | 2007-05-01 | 2012-12-26 | テイカ製薬株式会社 | 創傷被覆組成物および創傷被覆材 |
| JP2009091330A (ja) * | 2007-10-11 | 2009-04-30 | Nitto Boseki Co Ltd | シラン化合物、及びその加水分解物で処理したガラス繊維基材 |
| JP5349873B2 (ja) | 2008-09-04 | 2013-11-20 | 大阪有機化学工業株式会社 | 医療用材料 |
| JP2011136985A (ja) * | 2009-12-03 | 2011-07-14 | Nof Corp | チオエーテル含有アルコキシシラン誘導体および用途 |
| JP5597018B2 (ja) * | 2010-04-09 | 2014-10-01 | 大阪有機化学工業株式会社 | ２液型表面改質剤 |
| CN102020672B (zh) * | 2010-10-09 | 2013-08-21 | 华南理工大学 | 烷氧基硅烷官能化甜菜碱型两性离子化合物及其制备方法与应用 |
| JP2012148436A (ja) * | 2011-01-17 | 2012-08-09 | Osaka Organic Chem Ind Ltd | 低反射性材料 |
-
2012
- 2012-08-28 JP JP2013533597A patent/JP6150071B2/ja active Active
- 2012-08-28 WO PCT/JP2012/071697 patent/WO2013038901A1/ja active Application Filing
- 2012-08-28 US US14/345,002 patent/US9340561B2/en active Active
- 2012-09-11 TW TW101133127A patent/TWI565710B/zh active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105744966A (zh) * | 2013-11-28 | 2016-07-06 | 东丽株式会社 | 抗血栓性材料 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9340561B2 (en) | 2016-05-17 |
| JPWO2013038901A1 (ja) | 2015-03-26 |
| WO2013038901A1 (ja) | 2013-03-21 |
| TWI565710B (zh) | 2017-01-11 |
| US20140370182A1 (en) | 2014-12-18 |
| JP6150071B2 (ja) | 2017-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI565710B (zh) | 有機矽化合物及含該化合物之矽烷偶合劑 | |
| JP5935224B2 (ja) | ｉＰＳ細胞の腫瘍化を抑制することが可能な分化誘導方法 | |
| TWI637055B (zh) | 多能性幹細胞的製備方法、使用該製備方法而製備出多能性幹細胞、改善劑、以及該多能性幹細胞之分化誘導方法 | |
| WO2018025767A1 (ja) | ブロック共重合体およびそれを用いた表面処理剤 | |
| US7923246B2 (en) | Method of culturing embryonic stem cells with the use of amniotic membrane-origin factor | |
| JP6375358B2 (ja) | 細胞培養用組成物及び細胞培養器 | |
| JP2016131561A (ja) | 細胞を回収する方法、及びそれに用いられるポリマー | |
| US20150044770A1 (en) | Method for selective cell attachment/detachment, cell patternization and cell harvesting by means of near infrared rays | |
| US11149252B2 (en) | Cell mass, cell structure, and three-dimensional tissue body | |
| CN113136367A (zh) | 一种纹状体类器官的制备方法和应用 | |
| EP3719113A1 (en) | Cell culture container capable of long-term culture, and method for manufacturing same | |
| WO2013051479A1 (ja) | 生体物質又は細胞の付着抑制剤 | |
| CN107531851A (zh) | 具有抑制生物材料附着的能力的离子复合物材料及其制造方法 | |
| WO2017131241A1 (ja) | 細胞塊、細胞構造体及び立体組織体 | |
| JP2016063801A (ja) | 細胞培養用支持体と、それを用いた細胞培養方法 | |
| WO2021065984A1 (ja) | 心筋細胞のシート化方法 | |
| KR100937456B1 (ko) | 인간배아줄기세포를 조골세포 직계열로 분화시키는 방법 | |
| JP6332646B2 (ja) | 活性エステル基を含有するシラン化合物とそれを用いた材料 | |
| WO2013176084A1 (ja) | シリルアルキルホスホラミダード化合物を含むシランカップリング剤 | |
| JP6901252B2 (ja) | 接着性細胞培養用基材、ならびにこれを利用した細胞培養容器および細胞培養方法 | |
| US20150337260A1 (en) | Hybrid Matrix | |
| Patel | A spin-coated thermoresponsive substrate for rapid cell sheet detachment and its applications in cardiac tissue engineering | |
| da Cruz Barros | Self-assembling nanofiber hydrogels to attenuate epithelial mesenchymal transition in lens epithelial cells | |
| KR20180119512A (ko) | 고생존율 및 고기능성 내분비 세포클러스터의 제조방법 | |
| Lara | Modulation of Murine Embryonic Stem Cell Pluripotency Markers by Fluid Flow |